American researchers were interested in patients with dermatomyositis who did not develop cancers in addition to their muscle disease. Their immunological profile has been studied in the hope of identifying cancer risk factors other than the already known one of anti-TIF1-g autoantibody positivity:
- 10 new autoantibodies have been identified in two distinct cohorts of patients with dermatomyositis according to the date of onset of the cancer (at the time of diagnosis or later).
- the anti-CCAR1 autoantibody in particular appears to be protective.
The use of these new type immunological profiles will allow to better define protocols for the detection and monitoring of cancers in dermatomyositis.
